NASDAQ:ATXI Avenue Therapeutics (ATXI) Stock Price, News & Analysis → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free ATXI Stock Alerts $3.78 +0.07 (+1.89%) (As of 12:47 PM ET) Add Compare Share Share Today's Range$3.70▼$3.9950-Day Range$3.62▼$11.8852-Week Range$3.52▼$93.75Volume14,153 shsAverage Volume76,278 shsMarket Capitalization$3.55 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrends Get Avenue Therapeutics alerts: Email Address Avenue Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish5.55% of Float Sold ShortDividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews Sentiment-0.17Based on 15 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.25 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Avenue Therapeutics.Read more about Avenue Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.55% of the float of Avenue Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvenue Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avenue Therapeutics has recently increased by 169.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvenue Therapeutics does not currently pay a dividend.Dividend GrowthAvenue Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAvenue Therapeutics has received a 73.16% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Avenue Therapeutics is -0.99. Previous Next 1.6 News and Social Media Coverage News SentimentAvenue Therapeutics has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Avenue Therapeutics this week, compared to 10 articles on an average week.Search InterestOnly 1 people have searched for ATXI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows3 people have added Avenue Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avenue Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Avenue Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 17.34% of the stock of Avenue Therapeutics is held by institutions.Read more about Avenue Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Avenue Therapeutics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avenue Therapeutics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvenue Therapeutics has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Avenue Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Avenue Therapeutics Stock (NASDAQ:ATXI)Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Read More ATXI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATXI Stock News HeadlinesMay 29 at 4:27 AM | msn.comBPD: Body recovered from canal near Q Street and California AvenueMay 29 at 4:27 AM | msn.comVehicle fire reported on Walnut Avenue in CarmichaelMay 29 at 4:27 AM | msn.comHFR: Multiple units respond to house fire on 10th Avenue SWMay 28 at 4:14 PM | msn.comA portion of Indiana Avenue in Sheboygan is closed. Here's how long construction is expected to last.May 28 at 6:13 AM | finance.yahoo.comThe CAA Worst Road in Ontario is Hamilton's Aberdeen AvenueMay 28 at 6:13 AM | msn.comPickup truck drives into house on Suffolk AvenueMay 28 at 6:13 AM | msn.comFour cars involved in crash on 390 near Lexington AvenueMay 28 at 6:13 AM | msn.comDelhi's Rouse Avenue Court summons minister Atishi in a defamation caseMay 28 at 6:13 AM | msn.comRenovations to building at Main Street and Clinton Avenue to begin: What will be in there?May 27 at 10:09 PM | msn.comLogan Avenue warehouse burns early Monday, residents should expect smoke: WFPSMay 27 at 10:09 PM | msn.comNew Berlin crash; 1 dead, 3 others hurt on W. National AvenueMay 27 at 10:09 PM | yahoo.com1 person dead after crash on Atlantic Avenue in Delray BeachMay 16, 2024 | globenewswire.comAvenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)May 15, 2024 | investorplace.comATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q1 2024May 15, 2024 | globenewswire.comAvenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 3, 2024 | msn.comMultiple lane closures coming to Capitol Avenue in downtown IndyMay 3, 2024 | msn.comPickup truck hits girl, flees the scene on Lamar AvenueMay 2, 2024 | msn.com2 people in critical condition after shooting on Arlington Avenue in ChattanoogaMay 2, 2024 | msn.comCrash with injuries, entrapment reported on Hamilton Avenue in Springfield TownshipMay 2, 2024 | msn.comMelrose Avenue record shop celebrates vinyl albums, takes music collectors on a journey through timeMay 2, 2024 | msn.comBrickell Avenue is the priciest commercial street in MiamiMay 2, 2024 | msn.comMilwaukee's National Avenue will see its auto lanes cut. Other safety changes are comingMay 2, 2024 | msn.comCity Avenue in Lower Merion set to triple its apartment count, transforming the office and retail hubMay 2, 2024 | msn.comGirl critically injured in hit-and-run on Lamar AvenueMay 2, 2024 | msn.com'It's wholesome': Houston Avenue church to host gospel rap concert to spread love in communitySee More Headlines Receive ATXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today5/29/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATXI CUSIPN/A CIK1644963 Webwww.avenuetx.com Phone(781) 652-4500FaxN/AEmployees3Year Founded2015Profitability EPS (Most Recent Fiscal Year)($7.8817) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,380,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-391.98% Debt Debt-to-Equity RatioN/A Current Ratio2.34 Quick Ratio2.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.02 per share Price / Book1.93Miscellaneous Outstanding Shares940,000Free Float924,000Market Cap$3.66 million OptionableNot Optionable Beta-0.09 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Alexandra MacLean M.D. (Age 57)CEO & Director Comp: $413.2kMr. David Jin (Age 34)Interim CFO, COO & Corporate Secretary Dr. Lindsay Allan Rosenwald (Age 69)Executive Director Dr. Scott A. Reines M.D. (Age 77)Ph.D., Interim Chief Medical Officer Comp: $69.12kKey CompetitorsEdesa BiotechNASDAQ:EDSAFSD PharmaNASDAQ:HUGEImunonNASDAQ:IMNNRedHill BiopharmaNASDAQ:RDHLPieris PharmaceuticalsNASDAQ:PIRSView All CompetitorsInsidersFortress Biotech, Inc.Bought 5,578 shares on 9/8/2023Total: $301,212.00 ($54.00/share)Lindsay A Md RosenwaldBought 4,649 shares on 9/8/2023Total: $251,046.00 ($54.00/share)View All Insider Transactions ATXI Stock Analysis - Frequently Asked Questions Should I buy or sell Avenue Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATXI shares. View ATXI analyst ratings or view top-rated stocks. How have ATXI shares performed in 2024? Avenue Therapeutics' stock was trading at $12.0750 at the start of the year. Since then, ATXI shares have decreased by 69.4% and is now trading at $3.70. View the best growth stocks for 2024 here. Are investors shorting Avenue Therapeutics? Avenue Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 46,100 shares, an increase of 169.6% from the April 30th total of 17,100 shares. Based on an average daily trading volume, of 61,600 shares, the days-to-cover ratio is presently 0.7 days. Approximately 5.6% of the shares of the company are short sold. View Avenue Therapeutics' Short Interest. When is Avenue Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ATXI earnings forecast. How were Avenue Therapeutics' earnings last quarter? Avenue Therapeutics, Inc. (NASDAQ:ATXI) released its earnings results on Monday, March, 18th. The company reported $42.00 earnings per share (EPS) for the quarter. When did Avenue Therapeutics' stock split? Avenue Therapeutics shares reverse split on the morning of Friday, April 26th 2024. The 1-75 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of Avenue Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avenue Therapeutics investors own include Gilead Sciences (GILD), AbbVie (ABBV), Fulcrum Therapeutics (FULC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), CymaBay Therapeutics (CBAY), CytomX Therapeutics (CTMX) and Spero Therapeutics (SPRO). When did Avenue Therapeutics IPO? Avenue Therapeutics (ATXI) raised $30 million in an IPO on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager. How do I buy shares of Avenue Therapeutics? Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATXI) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaYou won't believe what Citigroup just did to it's depositorsAmerican AlternativeThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWrite this ticker symbol down…StocksToTradeNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.